Portal de Periódicos da CAPES

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

2016; Massachusetts Medical Society; Volume: 375; Issue: 3 Linguagem: Inglês

10.1056/nejmoa1514866

1533-4406

Nicole E. Basta, Adel A. F. Mahmoud, Julian Wolfson, Alexander Ploß, Brigitte Heller, Sarah Hanna, Peter Johnsen, R. Izzo, Bryan T. Grenfell, Jamie Findlow, Xilian Bai, Ray Borrow,

Virology and Viral Diseases

In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination would control the outbreak because isolates expressed antigens that were closely related to the vaccine antigens (factor H–binding protein [fHbp] and neisserial heparin-binding antigen). We quantified the immune responses induced by 4CMenB during the outbreak.